Contemporary OB/GYN week in review: UTIs, HIV-1, and more

Contemporary OB/GYN week in review: UTIs, HIV-1, and more

Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, April 22 - Friday, April 26 2024), and click each link to read and watch anything you may have missed.

1.) FDA approves Pivya for treating uncomplicated UTIs

FDA approves Pivya for treating uncomplicated UTIs | Image Credit: © Tada Images - © Tada Images - stock.adobe.com.

Explore the efficacy of Pivya (pivmecillinam; Utility Therapeutics) tablets in managing uncomplicated urinary tract infections in female adults, supported by controlled clinical trials and safety considerations.

Click here for the full article.

2.) FDA approves updated label for Biktarvy against HIV-1

FDA approves updated label for Biktarvy against HIV-1 | Image Credit: © muh - © muh - stock.adobe.com.

Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.

Click here for the full article.

3.) Survey shows growing support for IVF coverage in US health care

Survey shows growing support for IVF coverage in US health care | Image Credit: © Monkey Business - © Monkey Business - stock.adobe.com.

A recent poll highlights increasing public demand for broader insurance coverage for in vitro fertilization, underscoring persistent barriers faced by millions without access to adequate fertility care.

Click here for the full article.

4.) Study finds antihypertensive treatment reduces uterine fibroids risk

Study finds antihypertensive treatment reduces uterine fibroids risk | Image Credit: © interstid - © interstid - stock.adobe.com.

A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.

Click here for the full article.

5.) Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation

Unraveling preeclampsia: Insights into heterogeneity and intravascular inflammation | Image Credit: © HENADZY - © HENADZY - stock.adobe.com.

A recent study delved into the intricate clusters of term preeclampsia, shedding light on its diverse manifestations and the pivotal role of intravascular inflammation, paving the way for improved classification and management strategies.

Click here for the full article.